Aprea Therapeutics (APRE) Common Equity (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Common Equity of $41.6 million for Q1 2026, up 167.45% year-over-year from $15.5 million in Q1 2025, and up 234.27% quarter-over-quarter from $12.4 million in Q4 2025.
Aprea Therapeutics (APRE) Common Equity (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Common Equity for 9 consecutive years, with $41.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 167.45% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $41.6 million (up 167.45% YoY), while the FY2025 annual figure was $12.4 million, down 35.56% from the prior year.
- Common Equity rose to $41.6 million in Q1 2026 per APRE's latest filing, from $12.4 million in the prior quarter.
- Across five years, Common Equity topped out at $43.6 million in Q1 2022 and bottomed at -$35.8 million in Q2 2022.
- Historically, Common Equity has averaged $19.8 million across 5 years, with a median of $21.9 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity plunged 158.7% — and 2026, when it soared 167.45%.
- Aprea Therapeutics' Common Equity stood at $25.6 million in 2022, then plunged by 33.89% to $17.0 million in 2023, then advanced by 13.88% to $19.3 million in 2024, then slumped by 35.56% to $12.4 million in 2025, then surged by 234.27% to $41.6 million in 2026.
- Business Quant data shows APRE's Common Equity at $41.6 million in Q1 2026, $12.4 million in Q4 2025, and $10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 38.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.47 Mn |
| Mar 31, 2026 | 41.59 Mn |
| Dec 31, 2025 | 12.44 Mn |
| Sep 30, 2025 | 10.91 Mn |
| Jun 30, 2025 | 13.41 Mn |
| Mar 31, 2025 | 15.55 Mn |
| Dec 31, 2024 | 19.31 Mn |
| Sep 30, 2024 | 21.95 Mn |
| Jun 30, 2024 | 25.56 Mn |
| Mar 31, 2024 | 28.92 Mn |
| Dec 31, 2023 | 16.95 Mn |
| Sep 30, 2023 | 20.29 Mn |
| Jun 30, 2023 | 23.42 Mn |
| Mar 31, 2023 | 26.48 Mn |
| Dec 31, 2022 | 25.64 Mn |
| Sep 30, 2022 | 26.63 Mn |
| Jun 30, 2022 | -35.78 Mn |
| Mar 31, 2022 | 43.59 Mn |
| Dec 31, 2021 | 49.51 Mn |
| Sep 30, 2021 | 53.42 Mn |